Zarif Mohamed Sofian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zarif Mohamed Sofian has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Syed Mahmood
Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur 50603, Malaysia
6 shared publications - Yi Ge
School of Pharmacy, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
5 shared publications - Ramsha Khalid
Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur 50603, Malaysia
4 shared publications - Zamri Chik
Universiti Malaya Research Center for Biopharmaceuticals and Advanced Therapeutics (UBAT), Pharmacology Department, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
3 shared publications - Asif Nawaz
Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur 50603, Malaysia
2 shared publications - Dania Adila Ahmad Ruzaidi
Faculty of Applied Sciences, Universiti Teknologi Mara, Shah Alam 40450, Malaysia
2 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (4) , 336
Synthesis, Physicochemical Characterization and Antibacterial Assessment of Curcumin/2-Hydroxypropyl-β-Cyclodextrin-Functionalized Silver Nanoparticles (cAgNPs)
- 19 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (4) , 336
Open AccessSynthesis, Physicochemical Characterization and Antibacterial Assessment of Curcumin/2-Hydroxypropyl-β-Cyclodextrin-Functionalized Silver Nanoparticles (cAgNPs)
- Open Access
- 19 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (4) , 328
Evaluation of Chitosan-Methotrexate Nanoparticles Loaded in Alginate Beads for Controlled Drug Delivery Against Breast Cancer
- 19 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (4) , 328
Open AccessEvaluation of Chitosan-Methotrexate Nanoparticles Loaded in Alginate Beads for Controlled Drug Delivery Against Breast Cancer
- Open Access
- 20 October 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (6) , 1-22
Rapid Dissolvable Microneedles Integrated with Felodipine-Loaded Liposome: Fabrication, Characterizations, in-vitro and ex-vivo Evaluation
- 20 October 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (6) , 1-22
Open AccessRapid Dissolvable Microneedles Integrated with Felodipine-Loaded Liposome: Fabrication, Characterizations, in-vitro and ex-vivo Evaluation
- Open Access
- 31 July 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (8)
Correction: Khalid et al. Development of Rapidly Dissolving Microneedles Integrated with Valsartan-Loaded Nanoliposomes for Transdermal Drug Delivery: In Vitro and Ex Vivo Evaluation. Pharmaceutics 2025, 17, 483
In the original publication [...].
- 31 July 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (8)
Open AccessCorrection: Khalid et al. Development of Rapidly Dissolving Microneedles Integrated with Valsartan-Loaded Nanoliposomes for Transdermal Drug Delivery: In Vitro and Ex Vivo Evaluation. Pharmaceutics 2025, 17, 483
In the original publication [...].
- Open Access
- 31 July 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (8) , 996
Inhalable Nanomaterial Discoveries for Lung Cancer Therapy: A Review
Lung cancer remains one of the most common and deadliest forms of cancer worldwide despite notable advancements in its management. Conventional treatments, such as chemotherapy, often have limitations in effectively targeting cancer cells, which frequently lead to off-target side effects. In this context, the pulmonary delivery of inhalable nanomaterials offers the advantages of being rapid, efficient, and target-specific, with minimal systemic side effects. This concise review summarizes the basic research and clinical translation of inhalable nanomaterials for the treatment of lung cancer. We also provide insights into the latest advances in pulmonary drug delivery systems, focusing on various types of pulmonary devices and nanomaterials. Furthermore, this paper discusses significant challenges in translating the discoveries of inhalable nanomaterials into clinical care for lung cancer and shares strategies to overcome these issues.
- 31 July 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (8) , 996
Open AccessInhalable Nanomaterial Discoveries for Lung Cancer Therapy: A Review
Lung cancer remains one of the most common and deadliest forms of cancer worldwide despite notable advancements in its management. Conventional treatments, such as chemotherapy, often have limitations in effectively targeting cancer cells, which frequently lead to off-target side effects. In this context, the pulmonary delivery of inhalable nanomaterials offers the advantages of being rapid, efficient, and target-specific, with minimal systemic side effects. This concise review summarizes the basic research and clinical translation of inhalable nanomaterials for the treatment of lung cancer. We also provide insights into the latest advances in pulmonary drug delivery systems, focusing on various types of pulmonary devices and nanomaterials. Furthermore, this paper discusses significant challenges in translating the discoveries of inhalable nanomaterials into clinical care for lung cancer and shares strategies to overcome these issues.
- Open Access
Review on 3D Printing Filaments Used in Fused Deposition Modeling Method for Dermatological Preparations
Three-dimensional printing, particularly Fused Deposition Modeling (FDM), has revolutionized dermatological drug delivery by offering the ability to create personalized and precise drug formulations. This technology enables the design of customized drug delivery systems using a variety of polymers, such as Polylactic Acid (PLA), Polyvinyl Alcohol (PVA), Polyethylene Glycol (PEG), and Polycaprolactone (PCL), each with unique properties that enhance drug release, patient compliance, and treatment efficacy. This review analyzes these polymers in terms of their advantages, limitations, and suitability for dermatological applications. The ability to tailor these materials offers significant potential in overcoming treatment regimens. Additionally, the customization of three-dimensional-printed drug delivery systems provides a platform for creating patient-specific solutions that are more effective and adaptable to individual needs. Despite challenges such as moisture sensitivity and mechanical brittleness, the potential of FDM technology to improve dermatological treatments remains promising. The future of three-dimensional printing in dermatology lies in the integration of optimized materials and advanced printing techniques, which could further enhance patient-specific care and broaden the clinical applicability of these technologies in the pharmaceutical and biomedical sectors. By addressing these limitations and expanding material choices, FDM-based drug delivery systems have the potential to revolutionize the management of dermatological conditions, offering improved therapeutic outcomes and quality of life for patients.
Open AccessReview on 3D Printing Filaments Used in Fused Deposition Modeling Method for Dermatological Preparations
Three-dimensional printing, particularly Fused Deposition Modeling (FDM), has revolutionized dermatological drug delivery by offering the ability to create personalized and precise drug formulations. This technology enables the design of customized drug delivery systems using a variety of polymers, such as Polylactic Acid (PLA), Polyvinyl Alcohol (PVA), Polyethylene Glycol (PEG), and Polycaprolactone (PCL), each with unique properties that enhance drug release, patient compliance, and treatment efficacy. This review analyzes these polymers in terms of their advantages, limitations, and suitability for dermatological applications. The ability to tailor these materials offers significant potential in overcoming treatment regimens. Additionally, the customization of three-dimensional-printed drug delivery systems provides a platform for creating patient-specific solutions that are more effective and adaptable to individual needs. Despite challenges such as moisture sensitivity and mechanical brittleness, the potential of FDM technology to improve dermatological treatments remains promising. The future of three-dimensional printing in dermatology lies in the integration of optimized materials and advanced printing techniques, which could further enhance patient-specific care and broaden the clinical applicability of these technologies in the pharmaceutical and biomedical sectors. By addressing these limitations and expanding material choices, FDM-based drug delivery systems have the potential to revolutionize the management of dermatological conditions, offering improved therapeutic outcomes and quality of life for patients.
- Open Access
- 7 April 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (4) , 483
Development of Rapidly Dissolving Microneedles Integrated with Valsartan-Loaded Nanoliposomes for Transdermal Drug Delivery: In Vitro and Ex Vivo Evaluation
Background: Hypertension (HTN) is recognized as a major risk factor for cardiovascular disease, chronic kidney disease, and peripheral artery disease. Valsartan (VAL), an angiotensin receptor blocker drug for hypertension, has been limited due to its poor solubility and poor absorption from the GIT, which leads to low oral bioavailability. Objectives/Method: In the present research, firstly, VAL-loaded nanoliposomes were formulated and optimized using the Box–Behnken design (BBD). Optimized VAL-nanoliposomes were physically characterized and their fate was examined by scanning and transmission microscopy, DSC, FTIR, XRD, and ex vivo studies using rat skin. In vitro studies using human keratinocyte (HaCaT) cells showed a decrease in cell viability as the liposome concentration increased. Secondly, the formulation of VAL-loaded nanoliposomes was integrated into dissolvable microneedles (DMNs) to deliver the VAL transdermally, crossing the skin barrier for better systemic delivery. Results: The optimized nanoliposomes showed a vesicle size of 150.23 (0.47) nm, a ZP of −23.37 (0.50) mV, and an EE% of 94.72 (0.44)%. The DMNs were fabricated using a ratio of biodegradable polymers, sodium alginate (SA), and hydroxypropyl methylcellulose (HPMC). The resulting VAL-LP-DMNs exhibited sharp pyramidal microneedles, adequate mechanical properties, effective skin insertion capability, and rapid dissolution of the microneedles in rat skin. In the ex vivo analysis, the transdermal flux of VAL was significantly (5.36 (0.39) μg/cm2/h) improved by VAL-LP-DMNs. The enhancement ratio of the VAL-LP-DMNs was 1.85. In conclusion, liposomes combined with DMNs have shown high potential and bright prospects as carriers for the transdermal delivery of VAL. Conclusions: These DMNs can be explored in studies focused on in vivo evaluations to confirm their safety, pharmacokinetics profile, and pharmacodynamic efficacy.
- 7 April 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (4) , 483
Open AccessDevelopment of Rapidly Dissolving Microneedles Integrated with Valsartan-Loaded Nanoliposomes for Transdermal Drug Delivery: In Vitro and Ex Vivo Evaluation
Background: Hypertension (HTN) is recognized as a major risk factor for cardiovascular disease, chronic kidney disease, and peripheral artery disease. Valsartan (VAL), an angiotensin receptor blocker drug for hypertension, has been limited due to its poor solubility and poor absorption from the GIT, which leads to low oral bioavailability. Objectives/Method: In the present research, firstly, VAL-loaded nanoliposomes were formulated and optimized using the Box–Behnken design (BBD). Optimized VAL-nanoliposomes were physically characterized and their fate was examined by scanning and transmission microscopy, DSC, FTIR, XRD, and ex vivo studies using rat skin. In vitro studies using human keratinocyte (HaCaT) cells showed a decrease in cell viability as the liposome concentration increased. Secondly, the formulation of VAL-loaded nanoliposomes was integrated into dissolvable microneedles (DMNs) to deliver the VAL transdermally, crossing the skin barrier for better systemic delivery. Results: The optimized nanoliposomes showed a vesicle size of 150.23 (0.47) nm, a ZP of −23.37 (0.50) mV, and an EE% of 94.72 (0.44)%. The DMNs were fabricated using a ratio of biodegradable polymers, sodium alginate (SA), and hydroxypropyl methylcellulose (HPMC). The resulting VAL-LP-DMNs exhibited sharp pyramidal microneedles, adequate mechanical properties, effective skin insertion capability, and rapid dissolution of the microneedles in rat skin. In the ex vivo analysis, the transdermal flux of VAL was significantly (5.36 (0.39) μg/cm2/h) improved by VAL-LP-DMNs. The enhancement ratio of the VAL-LP-DMNs was 1.85. In conclusion, liposomes combined with DMNs have shown high potential and bright prospects as carriers for the transdermal delivery of VAL. Conclusions: These DMNs can be explored in studies focused on in vivo evaluations to confirm their safety, pharmacokinetics profile, and pharmacodynamic efficacy.
- 22 December 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 651, 123735
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
- 22 December 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 651, 123735
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
- Open Access
- 27 July 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (8) , 2029
Microneedles and Their Application in Transdermal Delivery of Antihypertensive Drugs—A Review
One of the most cutting-edge, effective, and least invasive pharmaceutical innovations is the utilization of microneedles (MNs) for drug delivery, patient monitoring, diagnostics, medicine or vaccine delivery, and other medical procedures (e.g., intradermal vaccination, allergy testing, dermatology, and blood sampling). The MN-based system offers many advantages, such as minimal cost, high medical effectiveness, comparatively good safety, and painless drug application. Drug delivery through MNs can possibly be viewed as a viable instrument for various macromolecules (e.g., proteins, peptides, and nucleic acids) that are not efficiently administered through traditional approaches. This review article provides an overview of MN-based research in the transdermal delivery of hypertensive drugs. The critical attributes of microneedles are discussed, including the mechanism of drug release, pharmacokinetics, fabrication techniques, therapeutic applications, and upcoming challenges. Furthermore, the therapeutic perspective and improved bioavailability of hypertensive drugs that are poorly aqueous-soluble are also discussed. This focused review provides an overview of reported studies and the recent progress of MN-based delivery of hypertensive drugs, paving the way for future pharmaceutical uses. As MN-based drug administration bypasses first-pass metabolism and the high variability in drug plasma levels, it has grown significantly more important for systemic therapy. In conclusion, MN-based drug delivery of hypertensive drugs for increasing bioavailability and patient compliance could support a new trend of hypertensive drug delivery and provide an alternative option, overcoming the restrictions of the current dosage forms.
- 27 July 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (8) , 2029
Open AccessMicroneedles and Their Application in Transdermal Delivery of Antihypertensive Drugs—A Review
One of the most cutting-edge, effective, and least invasive pharmaceutical innovations is the utilization of microneedles (MNs) for drug delivery, patient monitoring, diagnostics, medicine or vaccine delivery, and other medical procedures (e.g., intradermal vaccination, allergy testing, dermatology, and blood sampling). The MN-based system offers many advantages, such as minimal cost, high medical effectiveness, comparatively good safety, and painless drug application. Drug delivery through MNs can possibly be viewed as a viable instrument for various macromolecules (e.g., proteins, peptides, and nucleic acids) that are not efficiently administered through traditional approaches. This review article provides an overview of MN-based research in the transdermal delivery of hypertensive drugs. The critical attributes of microneedles are discussed, including the mechanism of drug release, pharmacokinetics, fabrication techniques, therapeutic applications, and upcoming challenges. Furthermore, the therapeutic perspective and improved bioavailability of hypertensive drugs that are poorly aqueous-soluble are also discussed. This focused review provides an overview of reported studies and the recent progress of MN-based delivery of hypertensive drugs, paving the way for future pharmaceutical uses. As MN-based drug administration bypasses first-pass metabolism and the high variability in drug plasma levels, it has grown significantly more important for systemic therapy. In conclusion, MN-based drug delivery of hypertensive drugs for increasing bioavailability and patient compliance could support a new trend of hypertensive drug delivery and provide an alternative option, overcoming the restrictions of the current dosage forms.